Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Bodei

Showing results (181-190 of 184) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 184 results.
European Journal of Nuclear Medicine and Molecular Imaging|May 29, 2023
Joint EANM/SNMMI procedure guideline for the use of <sup>177</sup>Lu-labeled PSMA-targeted radioligand-therapy (<sup>177</sup>Lu-PSMA-RLT)Clemens Kratochwil, Wolfgang P Fendler, Matthias Eiber, et al.
The Lancet. Oncology|July 3, 2026
Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS)Christophe M Deroose, Hannes Leupe, Rodney J Hicks, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 4, 2020
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate: an analysis of the NETTER-1 studyJonathan Strosberg, Pamela L Kunz, Andrew Hendifar, et al.
Nature Genetics|June 20, 2018
A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumorsMariano J Alvarez, Prem S Subramaniam, Laura H Tang, et al.
Pageof 19

Showing results (181-190 of 184) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 184 results.
European Journal of Nuclear Medicine and Molecular Imaging|May 29, 2023
Joint EANM/SNMMI procedure guideline for the use of <sup>177</sup>Lu-labeled PSMA-targeted radioligand-therapy (<sup>177</sup>Lu-PSMA-RLT)Clemens Kratochwil, Wolfgang P Fendler, Matthias Eiber, et al.
The Lancet. Oncology|July 3, 2026
Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS)Christophe M Deroose, Hannes Leupe, Rodney J Hicks, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 4, 2020
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate: an analysis of the NETTER-1 studyJonathan Strosberg, Pamela L Kunz, Andrew Hendifar, et al.
Nature Genetics|June 20, 2018
A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumorsMariano J Alvarez, Prem S Subramaniam, Laura H Tang, et al.
Pageof 19